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Abstract
Introduction: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by autoreactive T and B 
cells, which are believed to be secondary to deficient dendritic cells (DCs). However, whether DC abnormalities occur 
during their development in the bone marrow (BM) or in the periphery is not known.
Methods: Thirteen patients with SLE and 16 normal controls were recruited. We studied the morphology, phenotype, 
and functional abilities of bone marrow-derived dendritic cells (BMDCs) generated by using two culture methods: 
FMS-like tyrosine kinase 3 (Flt3)-ligand (FL) and granulocyte-macrophage colony-stimulating factor (GM-CSF) plus 
interleukin-4 (IL-4), respectively.
Results: BMDCs induced by FL exhibited both myeloid (mDC) and plasmacytoid DC (pDC) features, whereas GM-CSF/
IL-4 induced mDC generation. Substantial phenotypic and functional defects of BMDCs were found from patients with 
SLE at different stages of cell maturation. When compared with healthy controls, SLE immature BM FLDCs expressed 
higher levels of CCR7. Both immature and mature SLE BM FLDCs expressed higher levels of CD40 and CD86 and 
induced stronger T-cell proliferation. SLE BM mDCs expressed higher levels of CD40 and CD86 but lower levels of HLA-
DR and a lower ability to stimulate T-cell proliferation when compared with control BM mDCs.
Conclusions: Our data are in accordance with previous reports that suggest that DCs have a potential pathogenic role 
in SLE. Defects of these cells are evident during their development in BM. BM mDCs are deficient, whereas BM pDCs, 
which are part of BM FLDCs, are the likely culprit in inducing autoimmunity in SLE.
Introduction
Systemic lupus erythematosus (SLE) is a multisystemic
autoimmune disease characterized by autoreactive T and
B cells [1,2]. Dendritic cells (DCs), the most effective anti-
gen-presenting cells (APCs), are capable of activating
naïve T cells and initiating T-cell responses. DCs have
been hypothesized to play an important role in the patho-
genesis of SLE [3,4].
DCs are developed in the bone marrow (BM), released
into the circulation, and subsequently home to many tis-
sues. The function of DCs varies according to their stage
of maturity. Immature DCs are capable of capturing and
processing antigens (Ags). After migration to the lym-
phoid organs, where they become mature, their ability to
capture and process Ags decreases, whereas that for Ag
presentation increases [5]. After maturation, DCs are
capable of inducing the differentiation of naïve T cells
into T-helper cells [6] with increased expression of adhe-
sion molecules and cytokine receptors and cytokine pro-
duction [7,8]. Activation of T cells requires two signals,
the engagement of the T-cell receptor/CD3 complex with
the antigenic peptide presented by the major histocom-
patibility complex (MHC), and the presence of co-stimu-
latory molecules and their ligands [6]. DCs could supply
both signals for T-cell activation.
Two subsets of peripheral DCs have been identified in
humans on the basis of their expression of CD11c:
CD11c+ myeloid DCs (mDCs) and CD11c- plasmacytoid
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Page 2 of 12DCs (pDCs) [6,9,10]. Priming naïve T cells through Ag
capture and presentation is the unique property of
mDCs, whereas pDCs are inefficient in capturing Ag at
all stages of development [11]. The site of distribution of
the two subsets of DCs is different, too. mDCs are located
mainly in the skin and mucosal tissues. Conversely, pDCs
exist mainly within lymphoid tissues and may therefore
be the major subset of APCs that recognize self-Ag and
are responsible for immune tolerance [12].
In SLE, abnormalities in peripheral blood-isolated DCs,
monocyte-derived DCs, and mouse BM-derived DCs
have been reported [3,7,8,13,14]. All of these studies have
indicated a crucial role of DCs in the pathogenesis of SLE
through either a deficiency in sustaining peripheral toler-
ance to self-Ag or an increased susceptibility to infection.
SLE serum has also been shown to induce DC generation,
suggesting that some of the observed DC functional
abnormalities may be acquired [15]. Whether SLE DC
abnormalities occur during their development within the
BM or as a result of microenvironmental changes or Ag
capture in the peripheral blood and tissues, or both,
remains unknown.
Two methods have been used to generate BM DCs
(BMDCs). One uses culture of the BM cells in FMS
tyrosine kinase 3 (Flt3)-ligand (FL), whereas the other
uses granulocyte-macrophage colony-stimulating factor
(GM-CSF) plus interleukin-4 (IL-4) to induce DC genera-
tion. Treatment of mouse BM with FL results in the
expansion of both mDCs and pDCs, whereas GM-CSF/
IL-4 treatment favors only the production of mDCs. Thus
far, no culture methods have been identified that will gen-
erate pDCs alone from BM in vitro. The primary aim of
this study was to explore whether FL- or GM-CSF/IL-4-
generated BMDCs from patients with SLE were abnormal
when compared with healthy controls. We analyzed the
morphology, phenotype and functional ability of these
DCs at different stages of development.
Materials and methods
Patients and controls
Patients who fulfilled the American College of Rheuma-
tology classification criteria for SLE [16] were recruited
from the Rheumatology Clinic of Queen Mary Hospital,
Hong Kong. They had either cytopenia or fever requiring
BM examination as part of their clinical investigations.
The Systemic Lupus Erythematosus Disease Activity
Index (SLEDAI) was used as a measure of overall disease
activity [17]. Active disease was defined by an SLEDAI
score of ≥ 6. None of the patients in this report had fever
secondary to an underlying infection. Control subjects
were BM donors of the Queen Mary Hospital Bone Mar-
row Transplantation Program. This study was approved
by the Hong Kong University/Hong Kong West Cluster
Institutional Review Board. A written informed consent
was obtained from all subjects.
Generation of BM-derived immature and mature DCs
DCs were obtained according to the methods reported
previously, with some modifications [18]. In brief, human
iliac crest BM cells (BMCs) were freshly aspirated from
SLE patients or from BM donors. They were then isolated
by Ficoll-Hypaque gradients. The BMCs used for DC cul-
ture were depleted of CD3+ cells by anti-CD3 mAb-
coated magnetic beads (Miltenyi Biotech Inc., Sunnyvale,
CA, USA). The medium for DC generation consisted of
RPMI-1640 supplemented with 10% fetal bovine serum
(FBS), 100 U/ml penicillin, and 100 μg/ml streptomycin
(Sigma Chemical, San Diego, CA). Aliquots of 2 × 106
cells were placed into six-well plates in culture medium
containing 80 ng/ml FL (PharMingen, San Diego, CA,
USA) or 20 ng/ml of GM-CSF (Biosource, Camarillo, CA,
USA) plus 20 ng/ml IL-4 (PharMingen, San Diego, CA,
USA). On day 4 or 5, culture medium was replaced with
fresh medium.
After 8 days, nonadherent cells were harvested and
washed once, and 1 × 106 cell aliquots were then trans-
ferred into the wells of additional six-well plates and were
cultured with fresh medium for 3 additional days. Cells
harvested from this culture were designated immature
DC-enriched population. We found that FL cultured
BMDCs exhibited features of both mDCs and pDCs (des-
ignated BM FLDCs), whereas GM-CSF/IL-4-cultured
BMDCs exhibited features of mDCs (BM mDCs). To pro-
mote BMDC maturation, immature BM FLDCs were cul-
tured for an additional 2 days with 80 ng/ml FL, 2 μmol/L
oligodeoxynucleotide [ODN] containing unmethylated
CpG motifs(CpG ODN)2006 and 2 μmol/L CpG ODN
2216 (InvivoGen, San Diego, CA, USA), 50 ng/ml tumor
necrosis factor (TNF)-α (PharMingen), and 25 ng/ml
lipopolysaccharide (LPS). Immature BM mDCs were cul-
tured for an additional 3 days with 50 ng/ml TNF-α, 25
ng/ml LPS, 20 ng/ml GM-CSF, and 20 ng/ml IL-4 to
become mature BM mDCs.
Determination of cell morphology
Of the cells, 1 × 105 were centrifuged onto microscope
slides with Cytopro 7620 (Wescor Inc., Provo, Utah,
USA), stained with May-Grunwald-Giemsa solution and
analyzed with light microscopy (Olympus, Tokyo, Japan).
Phenotypic analysis of BM-derived immature and mature 
FLDCs and mDCs
Cells were incubated with 20 μl of either anti-CD3-FITC,
anti-CD19-FITC, anti-CD34-FITC, anti-CD40-FITC,
anti-HLA-DR-FITC, anti-DC-SIGN-FITC, anti-CD83-
PE, anti-CD86-PE, anti-CD45RA-PE, anti-CD123-PE-
CY5, anti-CD80-PE-CY5, or anti-CD11c-PE-CY5
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excess antibodies, the cells were analyzed with FACScan
Immunocytometry (BD Pharmingen). Appropriate iso-
type-matched control antibodies were included as nega-
tive controls.
IFN-α production assays
Supernatants of immature and mature BM FLDC and
mDC cultures were examined for the production of inter-
feron (IFN)-α by using the human IFN-α ELISA kit (Invit-
rogen Corporation, San Diego, CA, USA) according to
the manufacturer's instructions. Five normal donors and
three patients with SLE were studied.
Proliferation assays
Allogeneic T cells were negatively isolated from normal
donors' peripheral blood mononuclear cells (PBMCs) by
using a Pan T-cell isolation Kit (Miltenyi Biotech, Glad-
bach, Germany), which yielded a purity of >95%, as
assessed by CD3 expression. These purified T cells were
then used as responder cells (Rs) in all subsequent prolif-
eration assays. Before T-cell co-cultures, BMDCs were
treated with mitomycin C. Allogeneic mitomycin C-
treated BMDC-enriched populations were used as stimu-
lators (Ss). Mitomycin C is an antitumoral antibiotic that
has the ability to inhibit proliferation without affecting
the viability of the feeder cells in long-term culture
assays, thus reducing the interference of continued
growth of these cells on the proliferation of the co-cul-
tured responder cells [19]. Cell cultures were prepared
with 1 × 105 T cells/well and 5 × 104 BMDCs/well (the R/S
ratio is 2:1) in a 96-well plate, incubated for 4 days in 5%
CO2 at 37°C, pulsed with 0.5 μCi 3H-thymidine (3H-TdR)
for 16 hours, and then harvested and counted for radioac-
tivity by using a beta scintillation counter (Packard
Instruments, Chicago, IL, USA). Results are expressed as
median counts per minute (cpm) of triplicate samples.
Statistical methods
Statistical analysis was performed by using the unpaired
two-tailed Student's t test with Microsoft Excel computer
software program (Microsoft Corporation, Redmond,
WA, USA).
Results
Subjects
Thirteen patients with SLE, all women, aged 26~57
(mean, 43 ± 9.5) years, were studied. Nine of 13 patients
had active disease (SLEDAI ≥ 6). A summary of the clini-
cal details of these patients is shown in Table 1. Sixteen
healthy subjects, six male and 10 female, were recruited
as controls. They were aged from 23~60 (mean, 45 ± 11)
years.
Generation of DCs from BM cultures and analysis of control 
BMDCs
Previous reports showed that the administration of FL to
mouse BMCs generates large numbers of BMDCs in vivo
and in vitro [20-22]. To determine whether FL had the
same effects in humans, in addition to using GM-CSF/IL-
4, we used FL to induce BMDC generation from both
healthy donors and patients with SLE. Morphologic and
phenotypic analysis of control BM mDCs and FLDCs are
described subsequently.
Morphologic analysis of control BMDCs
As can be seen in Figure 1, cells cultured with either FL or
GM-CSF/IL-4 became larger and developed typical den-
dritic cytoplasmic extensions. Figure 1a shows the mor-
phology of CD3- BMCs. Figure 1b and 1d depicts
representative photomicrographs of immature and
mature BM FLDCs, respectively, and Figure 1c and 1e
shows immature and mature BM mDCs induced by GM-
CSF/IL-4. No obvious differences were noted between
immature and mature BM FLDCs or immature and
mature BM mDCs. However, when compared with
mDCs, some of the FLDCs had bigger nuclei, less cyto-
plasm, and fewer dendritic extensions.
Phenotyic analysis of control BMDCs
CD3- BMCs and immature and mature BMDCs were
stained with appropriate antibodies and analyzed with
flow cytometry. No detectable CD3+ cells and less than
1% of CD34+ and less than 3% of CD19+ cell impurities
were noted in the DC-enriched populations (data not
shown).
Immature and mature BM FLDCs expressed increased
levels of DC-SIGN, CD11c, HLA-DR, CD40, CD45RA,
CD80, CD83, and CD86 when compared with CD3- BMC
(P < 0.05 for all surface markers). The BM FLDC-
enriched population expressed higher BDCA-2 and
CD123 counts when compared with CD3- BMCs (P <
0.05 for BDCA-2 and P < 0.01 for CD123) (Figure 2a).
With GM-CSF/IL-4, immature and mature BM mDCs
showed significantly increased expression of DC-SIGN,
CD11c, HLA-DR, CD40, CD45RA, CD80, CD83, and
CD86 when compared with CD3- BMCs (P < 0.05 for all
surface markers). However, both immature and mature
BM mDCs expressed lower levels of BDCA-2 and CD123
(Figure 2a).
DC-SIGN+ mature BM FLDCs included CD11c+ (per-
centage of positive cells = 47.276 ± 23.354) and CD123+
(percentage of positive cells = 37.236 ± 9.921) cell popula-
tions. However, mature DC-SIGN+ BM mDCs expressed
CD11c (percentage of positive cells = 51.45 ± 26.435; no
significant difference was noted when compared with
mature FLDCs), but lower CD123 (percentage of positive
cells = 14.696 ± 5.177; P < 0.05 when compared with
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mature BM FLDCs expressed similar levels of CD11c and
CD123, whereas immature BM mDCs expressed similar
levels of CD11c but lower levels of CD123 expression
when compared with mature BM mDCs (data not
shown).
Analysis of SLE BMDCs: comparison with control BMDCs
Phenotypic expression
Mature BM FLDCs and mDCs from both SLE patients
and normal controls expressed increased CCR7 when
compared with immature BM FLDCs and BM immature
mDCs. However, SLE immature BM FLDCs expressed
higher CCR7 than did controls. Figure 4 shows the CCR7
results from three patients with SLE and three normal
controls.
SLE immature BM FLDCs expressed higher levels of
DC-SIGN (SLE versus controls = 12.311 ± 1.286 versus
1.241 ± 0.262; p < 0.01) and CD40 (SLE versus controls =
1.629 ± 0.35 versus 0.312 ± 0.255; P < 0.01) than did nor-
mal controls. SLE immature BM FLDCs expressed lower
levels of CD123 (SLE versus controls = 3.182 ± 0.956 ver-
sus 20.841 ± 14.258; P < 0.01), CD11c (SLE versus con-
trols = 11.149 ± 2.777 versus 47.918 ± 20.843; P < 0.05),
CD45-RA (SLE versus controls = 6.824 ± 2.663 versus
11.355 ± 3.925; P < 0.05) and HLA-DR (SLE versus con-
trols = 9.908 ± 4.211 versus 38.906 ± 9.129; P < 0.01) than
normal controls (Figure 2b).
SLE mature BM FLDCs expressed higher levels of DC-
SIGN (SLE versus controls = 12.711 ± 1.104 versus 1.595
± 0.424; P < 0.01), CD40 (SLE versus controls = 9.969 ±
5.729 versus 2.601 ± 1.582; P < 0.05) and CD45RA (SLE
versus controls = 44.950 ± 11.225 versus 29.352 ± 9.699; P
< 0.01) than normal controls. SLE mature BM FLDCs also
expressed higher levels of CD86 than normal controls,
although the difference was not statistically significant.
SLE mature BM FLDCs expressed lower levels of CD123
(SLE versus controls = 18.542 ± 7.997 versus 37.236 ±
9.921; P < 0.01) than controls. The levels of CD11c and
HLA-DR on SLE mature BM FLDCs were also lower than
those in normal controls, but the difference did not reach
statistical significance (Figure 2c).
SLE immature BM mDCs expressed higher levels of
DC-SIGN (SLE versus controls = 26.110 ± 12.064 versus
Table 1: Clinical and laboratory characteristics of the SLE patients studied
Case Current 
treatment
WBC
(×109/L)
Hb (g/dL) Plt
(×109/L)
Lym
(×109/L)
Anti-
dsDNA
Serum C3 Serum C4 24-hour 
UP
SLE-DAI
1 HCQ 200 mg/d 3.8 16.3 23 1.3 <5 54 13 0.24 3
2 Pred 5 mg/d, 
HCQ 200 mg/d
2.04 8.6 352 1.04 18 80 15 NA 1
3 Pred 12.5 mg/d, 
MMF 3 mg/d
10.55 9.2 281 0.45 34 72 24 6.57 6
4 HCQ 300 mg/d 2.38 12.1 149 0.64 127 29 7.1 <0.06 16
5 Pre 15 mg/d, 
HCQ 200 mg/d, 
Aza 100 mg/d
0.8 8.9 67 .3 19 94 19 0.18 6
6 Pred 20 mg/d, 
HCQ 400 mg/d
1.93 11.5 131 0.49 54 36 2.9 NA 15
7 Pred 7.5 mg/d, 
Aza 50 mg/d, 
MMF 1 mg/d
2.3 9.0 70 0.2 150 27 9.9 0.26 15
8 Pred 20 mg/d 4.9 10.4 207 1.4 9 67 13 NA 6
9 HCQ 200 mg/d 2.06 7.4 94 0.82 85 31 5.3 3.63 13
10 Pred 12.5 mg/d 
MMF 3 g/d
6.0 12.0 74 0.6 45 58 27 0.11 15
11 Pred 50 mg/d 3.54 9.4 47 0.9 29 101 34 NA 2
12 Pred 15 mg/d, 
HCQ 200 mg/d, 
Aza 100 mg/d
5.21 11.6 31 0.25 12 109 23 NA 1
13 HCQ 300 mg/d 4.1 9.5 92 1.2 >450 26 3.7 2.4 14
F, female; Pred, prednisolone;HCQ, hydroxychloroquine;Aza, azathioprine;MMF, mycophenolate mofetil;Hb, hemoglobin; WBC, white blood cell 
count [NR 4.1-10.9 × 109/L]; Plt, platelet count [NR 140-450 × 109/L]; Lym, lymphocyte count [NR 20-50% of WBCs]; SLEDAI, systemic lupus 
erythematosus disease activity index.
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Page 5 of 1211.179 ± 5.122; P < 0.05) and CD86 (SLE versus controls
= 31.575 ± 14.177 versus 8.652 ± 1.667; P < 0.01) but
lower levels of CD11c (SLE versus controls = 14.027 ±
4.169 versus 48.440 ± 19.606; P < 0.05), CD40 (SLE versus
controls = 5.332 ± 2.052 versus 14.851 ± 3.756; P < 0.01)
and HLA-DR (SLE versus controls = 37.833 ± 9.283 ver-
sus 56.862 ± 6.418; P < 0.01) (Figure 2d).
SLE mature BM mDCs expressed higher levels of DC-
SIGN (SLE versus controls = 45.877 ± 11.245 versus
18.710 ± 11.521; P < 0.05), CD86 (SLE versus controls =
60.243 ± 22.651 versus 29.305 ± 10.987; P < 0.01) and
CD80 (SLE versus controls = 40.601 ± 15.245 versus
20.970 ± 5.445; P < 0.01) but lower levels of CD40 (SLE
versus controls = 20.972 ± 9.855 versus 28.599 ± 4.847; P
< 0.05) than controls (Figure 2e).
Production of IFN-α
In SLE, both immature and mature BM FLDCs produced
detectable levels of IFN-α, whereas immature and mature
BM mDCs did not. Furthermore, mature BM FLDCs pro-
duced higher levels of IFN-α when compared with imma-
ture BM FLDCs (mature versus immature BM FLDCs =
65.59 ± 25.45 versus 10.52 ± 5.60 pg/ml; P = 0.022).
Because IFN-α is produced primarily by pDCs, these
results further suggest that BM FLDCs comprise a sub-
population of pDCs that are capable of responding to
CpG ODN stimulation.
In normal controls, no IFN-α was detected in the cul-
ture supernatants of either immature or mature BM
FLDCs and mDCs.
Mixed lymphocyte reaction
Both immature and mature SLE FLDCs expressed a
higher ability to induce T-cell proliferation when com-
pared with normal controls. As with normal control
mature mDCs, SLE mature mDCs induced higher T-cell
proliferation than did immature mDCs. SLE mature
mDCs tended to induce lower levels of T-cell prolifera-
tion when compared with control mature mDCs. How-
ever, the difference was not statistically significant (Figure
5).
Discussion
The immunopathogenesis of SLE is complex and is char-
acterized by multiple T- and B-cell abnormalities. Central
to these changes are believed to be altered functions of
DCs, the most important APCs [3,4,14,23-25].
Peripheral tolerance is believed to be broken in SLE
[26]. DCs, which have a significant role in maintaining
peripheral tolerance, have been found to be defective and
proposed to be important in the development of autoim-
munity in SLE [3]. Of the two DC subsets, pDCs are
thought to have a central role in SLE pathogenesis
through the production of IFN-α, which has a pivotal role
in inducing SLE [27,28]. Although controversial, the
number of pDCs in peripheral blood is aberrant when
compared with that in normal controls [4,24,29].
mDCs also have been found to be abnormal in SLE
[24,30,31]. Patients with this condition have deficient
number of mDCs [4] and monocyte-derived DCs that
Figure 1 SLE BMDCs cultured with FL alone (FLDCs) or GM - CSF + IL-4 (mDCs). Representative photographs of freshly isolated CD3- BMCs (a) and 
May-Grunwald-Giemsa-stained cytospin preparations of immature FLDCs (b), immature mDCs (c), mature FLDCs (d), and mature mDCs (e). BMDCs, 
bone marrow-derived dendritic cells; CD3- BMC, CD3- bone marrow cells; FLDC, dendritic cells induced by FL; FL, FMS-like tyrosine kinase 3 ligand; GM-
CSF, granulocyte macrophage-colony-stimulating factor; IL-4, interleukin 4; mDCs, myeloid dendritic cells.
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Figure 2 Phenotypic analysis of control and SLE BMDCs induced with FL or GM-CSF + IL-4. (a) Healthy control BMDCs induced with FL or GM-
CSF + IL-4. When compared with BMCs, both immature FLDCs and mDCs expressed DC-SIGN, CD11c, CD45RA, HLA-DR, CD40, CD80, CD83, and CD86. 
Expression of these molecules was higher in mature FLDCs and mDCs. Comparing FLDCs and mDCs, both immature and mature FLDCs expressed 
BDCA-2 and CD123, whereas immature and mature mDCs expressed no or low levels of these molecules. (b, c) Immature FLDCs and mature FLDCs 
from normal controls and patients with SLE. SLE immature and mature FLDCs expressed higher levels of DC-SIGN, CD123, and CD40 but lower levels 
of CD11c and HLA-DR than did controls. (d, e) Immature and mature mDCs from normal controls and patients with SLE. SLE immature and mature 
mDCs expressed higher levels of DC-SIGN and CD86 and lower CD40 than did those of normal controls. *P < 0.05; **P < 0.01. Results are represented 
as mean ± SD of independent experiments of seven SLE patients and eight normal controls. BMDCs, bone marrow-derived dendritic cells; BMCs, bone 
marrow cells; FLDCs, dendritic cells induced by FL; mDCs, myeloid dendritic cells; FL, FMS-like tyrosine kinase 3 ligand; GM-CSF, granulocyte mac-
rophage-colony stimulating factor; IL-4, interleukin 4.
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et al. [14] reported that monocyte-derived DCs from SLE
patients expressed high levels of CD86 and produced
increased quantities of IL-6 on stimulation.
Previous studies focused mostly on PBMC-derived DCs
or DCs that are directly isolated from peripheral blood
[24,33]. It is not known whether defects of these DCs are
secondary to (a) DC precursor deficiency; (b) microenvi-
ronmental changes in the bone marrow during DC devel-
opment; or (c) microenvironmental changes or after Ag
capture in the peripheral blood and the site of tissue
injury. Although murine BMDCs have been studied pre-
viously, data on the characteristics and function of
human BMDCs in patients with SLE is scarce. It is for this
reason that we compared the phenotypic and functional
characteristics of BMDCs from SLE patients and healthy
individuals.
Traditionally, DCs are generated in vitro by using GM-
CSF/IL-4 [34-37]. However, this method induces only
mDC generation. In mouse studies, FL has been reported
to be capable of inducing pDC development
[21,22,38,39]. Therefore, in our experiments, besides
using the traditional GM-CSF/IL-4 culture method to
study BM-derived mDCs, we also applied FL to induce
BM cells to develop into DCs (which we defined as BM
FLDCs), which showed features of both mDCs and pDCs
and allowed us to study BM-derived pDCs indirectly.
In the present study, we confirmed that human CD3-
BMCs could be induced to become DCs, with FL as the
only growth factor. Consistent with previous studies, BM
Figure 3 Phenotypic analysis of mature FLDCs and mature mDCs. Mature FLDCs expressed medium levels of CD11c and CD123, whereas mature 
mDCs expressed high levels of CD11c but only low levels of CD123. FLDCs, dendritic cells induced by FL; mDC, myeloid dendritic cells induced by GM-
CSF + IL-4; FL, FMS-like tyrosine kinase 3 ligand; GM-CSF, granulocyte macrophage-colony-stimulating factor; IL-4, interleukin 4.
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marker, and some costimulator molecules including
CD40, CD80, and CD86 when compared with BMCs and
the classic DC-culture system involving GM-CSF/IL-4
[35,37] which induced mainly mDC development. FL
appeared to induce both mDC and pDC development.
During differentiation, some of the BM FLDCs expressed
phenotypic characteristics (BDCA-2, CD123) similar to
those identified in pDCs, whereas others expressed
CD11c, which is normally seen in mDCs. In addition, we
found that FL-generated mDCs and pDCs existed in a
ratio of 1:1. This is consistent with findings reported in
previous studies on murine FLDCs derived from BM and
peripheral blood [21,39,40].
Figure 4 SLE (n = 3) immature FLDCs expressed higher CCR7 than normal (n = 3) immature FLDCs. (a) Mature FLDCs from both SLE patients 
and normal controls expressed higher-level of CCR7 than immature FLDCs. Immature FLDCs from SLE patients had a higher expression of CCR7 than 
did control. (b) Both control and SLE mature FLDCs and mDCs expressed higher levels of CCR7 than did immature FLDCs and mDCs, respectively. **P 
< 0.01; #P < 0.05. Results are expressed as mean ± standard deviation. NC, normal control; SLE, systemic lupus erythematosus; FLDCs, dendritic cells 
induced by FL; mDCs, myeloid dendritic cells induced by GM-CSF + IL-4; FL, FMS-like tyrosine kinase 3 ligand; GM-CSF, granulocyte macrophage-col-
ony-stimulating factor; IL-4, interleukin 4.
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of BMDCs at different stages of differentiation, various
agents were used to stimulate the maturation of these
cells. For immature BM mDCs, TNF-α/LPS were used to
stimulate their maturation. However, TNF-α/LPS have
not been used to stimulate immature pDCs previously. In
this study, therefore, we used CPG ODN2006/CPG
ODN2216 plus TNF-α/LPS to stimulate BM FLDCs.
After stimulation, BM FLDCs showed increased expres-
sion of CD80, CD86, CD40, and CD83, indicating that
these cells could be stimulated to maturity efficiently by
this method.
Results from our study showed that SLE BMDCs have
defective phenotypic expression and function when com-
pared with those from healthy subjects. CCR7 is a
chemokine receptor that is preferentially expressed by
mature DCs and is important for DC migration [41,42].
In our study, we found that immature BM FLDCs from
SLE patients expressed higher levels of CCR7 than did
those from normal controls, indicating that these cells
may have a stronger ability to migrate. Because no obvi-
ous differences in CCR7 expression were found between
SLE and normal immature BM mDCs, the higher expres-
sion of this chemokine receptor on SLE immature BM
FLDCs should have been contributed by the pDC popula-
tion among these cells. The higher CCR7 expression may
allow SLE pDCs to migrate into lymph nodes where they
could interact with T lymphocytes. This may also partly
explain the low number of pDCs found in the peripheral
blood of SLE patients in some previous studies [43,44].
However, to confirm that SLE pDCs have a higher ability
to migrate, further studies using an in vitro migration
assay are needed.
During DC maturation, HLA-DR expression is upregu-
lated. However, in patients with SLE, both BM FLDCs
and mDCs expressed lower levels of HLA-DR when com-
pared with controls. Previous studies have suggested that
deficiency in HLA-DR expression might be the cause of
increased susceptibility of patients with SLE to various
infections [32]. In our study, we found that SLE immature
and mature BM mDCs failed to stimulate T-cell prolifera-
tion as efficiently as did those obtained from normal con-
trols. This may be explained by their lower expression of
HLA-DR. However, this was not true for BM FLDCs.
Both immature and mature BM FLDCs stimulated higher
T-cell proliferation compared with controls. As BM
FLDCs include a mixed population of pDCs and mDCs
and because mDCs did not stimulate T-cell proliferation
Figure 5 Allogeneic T-cell proliferation induced directly by DCs. Bar graphs representing allogeneic T-cell proliferation induced by BMDCs from 
five patients with SLE and 11 normal controls. Both SLE immature and mature FLDCs induced higher T-cell proliferation, whereas SLE mDCs induced 
lower T-cell proliferation when compared with normal controls. **P < 0.01. Results are represented as mean ± SD of independent experiments. NC, 
normal control; SLE, systemic lupus erythematosus; FLDCs, dendritic cells induced by FL; mDCs, myeloid dendritic cells induced by GM-CSF + IL-4; FL, 
FMS-like tyrosine kinase 3 ligand; GM-CSF, granulocyte macrophage-colony-stimulating factor; IL-4, interleukin 4.
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tion may be attributed to the pDC subpopulation of BM
FLDCs. This effect may be related to the higher expres-
sion of CD40, CD80, and CD86 on SLE BM FLDCs than
in controls.
To evaluate whether BM FLDCs comprise a subpopula-
tion of pDCs and whether SLE BM FLDCs had higher
pDC activity, we measured the level of IFN-α by using
ELISA in the supernatants of BM FLDC and mDC cul-
tures. IFN-α is produced mainly by pDCs, and its serum
level has been reported to be higher in patients with SLE
[27,45]. In this preliminary analysis, we found that SLE
BM FLDCs produced detectable IFN-α, whereas normal
BM FLDCs did not. Furthermore, mature SLE BM FLDCs
produced higher levels of IFN-α than did immature SLE
BM FLDCs. Neither SLE nor control BM mDCs pro-
duced detectable IFN-α. These findings further con-
firmed that BM FLDCs consisted of both mDCs and
pDCs, as per earlier suggestion. It also confirmed that
pDCs were the more active of the two types of DCs in
SLE and may be the major culprit in inducing autoimmu-
nity in this condition. It should be noted that IFN-α mea-
surement was performed only in the BMDC culture
supernatants from a few subjects; further studies are
needed to confirm this finding. It is interesting to note
that a recent study showed that peripheral-blood pDCs
from patients with chronic SLE had decreased in vitro
IFN-α-producing capacity and were desensitized to TLR9
stimulation [13]. These data, plus those reported previ-
ously [3,7,8,13,14] and our current data on BMDCs pro-
vide further important insight into the role(s) of pDCs in
SLE pathogenesis. We hypothesize that pDCs are the
dominant DCs during their development in the BM.
These IFN-α-producing cells induce the development of
SLE. However, they may subsequently become deficient,
with reduced IFN-α producing capacity and tolerance to
TLR9 stimulation, probably as a result of chronic and
persistent exposure to DNA-containing immune com-
plexes in the peripheral environment, which are a hall-
mark of SLE.
Some limitations to our study exist. First, the number
of subjects studied was small. Second, our findings may
not be generalized to all patients with SLE, as the patients
recruited in this study all had some form of cytopenia or
fever requiring further investigations, including a BM
examination. Patients with other lupus manifestations
were not recruited, as we considered it unethical to per-
form a BM examination in these subjects. Third, most of
the patients studied were receiving some form of treat-
ment, including immunosuppressive agents. It is, there-
fore, not possible to confirm whether the BMDC changes
were a result of the underlying disease or that of the vari-
ous lupus medications. It should, however, be noted that
the majority of these patients had active lupus disease-
related cytopenia or fever despite drug treatment; it is
therefore tempting to suggest that our findings reflect the
true role of BMDCs in lupus disease pathogenesis. Future
studies should aim to recruit treatment-naïve or newly
diagnosed patients with SLE. However, this will have to
involve the collaboration of multiple lupus research units.
It has taken the authors more than 2 years to recruit 13
suitable patients from a cohort of more than 500 patients
for the purpose of this study. Alternately, future studies
may include culturing control BMDCs in vitro with the
various immunosuppressive drugs to evaluate whether
they acquire a similar phenotype to the one described in
this study.
Our study also did not examine whether the BMDC
changes were intrinsic defects or secondary to microenvi-
ronmental changes in the BM, including the cytokine
milieu in our SLE patients. This should be evaluated in
future studies. DC precursors in the bone marrow are
mainly CD34+ stem cells [35]. Sun and colleagues [46]
recently reported that CD34+ stem cells from patients
with SLE had abnormal expression of CD166 and CD123
and that these abnormalities correlated with the overall
lupus disease activity. Mesenchymal stem cells (MSCs),
an important compartment in the BM, are believed to be
able to affect DC generation, although previous findings
have been controversial [47,48]. Deficient MSCs from
patients with SLE have been reported [49], but whether
MSC may affect BMDC generation and functions
requires further detailed studies. In addition, the pheno-
types and functions of DCs from patients with SLE could
be altered by genetic defects in cell lineage, or as a result
of factors capable of inducing their differentiation and
maturation. Previous studies have shown higher levels of
multiple cytokines in the BM, some of which may be
pathogenic in SLE [50]. DCs from patients with SLE
could bear genetic alterations that made them prone to
maturation under abnormal conditions, or they may be
normal cells with an abnormal phenotype and behavior
induced by the bizarre microenvironment from which
they were obtained. Further investigations are required.
Conclusions
DCs have a significant role in antigen processing and pre-
sentation, leading to naïve T-cell stimulation or the devel-
opment of immune tolerance. Defects in DCs may lead to
an imbalance of the immune system, including alterations
of T and B cells, and may lead to autoimmunity, such as
the development of SLE. Here we suggest that both BM
mDCs and FLDCs from patients with SLE are defective.
Our results are in accordance with previous studies that
suggested that mDCs are deficient in patients with SLE
and may contribute to their susceptibility to infections,
but pDCs, which are part of FLDCs, are the major culprit
in SLE.
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